Announcements Trials
Browse Landscape

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Observation 23Blood Specimen Collection 20Drug Therapy 14Surveys and Questionnaires 10Surgical Procedures, Operative 8Immune Checkpoint Inhibitors 8Immunotherapy 7Positron Emission Tomography Computed Tomography 5Hematologic Tests 5Watchful Waiting 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Bevacizumab 4tislelizumab 3envafolimab 3darolutamide 3Tyrosine Kinase Inhibitors 3Therapeutics 3Standard of Care 3Radiotherapy 3Letrozole 3Indocyanine Green 3Imatinib Mesylate 3Endosonography 3Endoscopic Mucosal Resection 3Docetaxel 3Cyclophosphamide 3Capecitabine 3Artificial Intelligence 3pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Observational × neratinib × Clear all
NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Pierre Fabre Medicament

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡